A carregar...
Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway
Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), is the only approved TKI that is effective against T315I mutations in patients with chronic myeloid leukemia (CML). Specific activation of Notch signaling in CML cells by ponatinib can be considered as the “on-target effect” on the tumor...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7141219/ https://ncbi.nlm.nih.gov/pubmed/32197359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9030820 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|